SCHEMBL4437203

SCHEMBL4437203

c1ncc(CN2CCCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.49
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
TYK2 P29597 2/20 0.40
JAK3 P52333 2/20 0.40
HRH3 Q9Y5N1 2/20 0.39
ARG1 P05089 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 2/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SRPK1 Q96SB4 2/20 0.36
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17865300 0.98 LTA4H (0.48) LTA4HCHRNB2CHRNA4JAK2JAK1
SCHEMBL18427275 0.96 LTA4H (0.46) LTA4HCHRNB2CHRNA4JAK2JAK1
SCHEMBL13940676 0.86 LTA4H (0.40) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL14367254 0.83 KDM4E (0.47) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL207529 0.83 ALDH1A1 (0.47) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL15014625 0.80 PARG (0.37) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL9979865 0.80 ALDH1A1 (0.60) JAK2JAK1TYK2JAK3HRH3
SCHEMBL12767170 0.78 ALDH1A1 (0.43) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL209854 0.78 ARG1 (0.42) ARG1SMN1; SMN2ALDH1A1KDM4EHTT
SCHEMBL9976594 0.77 TLR8 (0.44) LTA4HJAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 US disclosed
US-8183241-B2 2-oxo-1-pyrrolidine derivatives UCB PHARMA, S.A. (BE) 2012-05-22 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 LTA4H 3590/4885CHRNB2 3612/4885CHRNA4 3536/4885
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LTA4H 4568/4885CHRNB2 4715/4885CHRNA4 4672/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LTA4H 4568/4885CHRNB2 4715/4885CHRNA4 4672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.